We are live on ! Find out more
EC

Euclidean Capital Portfolio holdings

AUM $392M
1-Year Est. Return 31.85%
This Fund
S&P 500
This Quarter Est. Return
+11.94%
1 Year Est. Return
+31.85%
3 Year Est. Return
+76.27%
5 Year Est. Return
-20.16%
10 Year Est. Return
–
AUM
$889M
AUM Growth
+$430M
Cap. Flow
+$359M
Cap. Flow %
40.39%
Top 10 Hldgs %
99.81%
Holding
13
New
–
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$299M
2
GLD icon
SPDR Gold Trust
GLD
+$60M

Top Sells

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$14

Sector Composition

Rank Sector Weight
1 Healthcare 7.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
State Street SPDR S&P 500 ETF Trust
SPY
$795B
$436M 49.06%
917,141
+670,891
+272% +$299M
GLD icon
2
SPDR Gold Trust
GLD
$131B
$266M 29.91%
1,390,000
+327,500
+31% +$60M
INDA icon
3
iShares MSCI India ETF
INDA
$6.89B
$118M 13.32%
2,425,144
– –
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$16.3M 1.84%
82,237
– –
ALEC icon
5
Alector
ALEC
$168M
$10.4M 1.17%
1,307,858
– –
FHTX icon
6
Foghorn Therapeutics
FHTX
$266M
$10.2M 1.14%
1,573,761
– –
ME
7
DELISTED
23andMe Holding Co
ME
$9.36M 1.05%
512,156
– –
ORIC icon
8
Oric Pharmaceuticals
ORIC
$1.15B
$9.1M 1.02%
989,410
– –
PMVP icon
9
PMV Pharmaceuticals
PMVP
$59.2M
$8.15M 0.92%
2,627,643
– –
TNYA icon
10
Tenaya Therapeutics
TNYA
$161M
$3.29M 0.37%
1,015,705
– –
NGM
11
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$852K 0.1%
992,168
– –
SRZN icon
12
Surrozen
SRZN
$258M
$824K 0.09%
87,696
-2
-0% -$14
SRZNW icon
13
Surrozen Inc Warrant
SRZNW
$3.31K ﹤0.01%
170,833
– –

Similar funds

WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
RC
Riposte Capital New York $392M AUM 69.08% 1-Year Est. Return
DCM
Divisar Capital Management San Francisco, California $392M AUM 108.45% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
BWM
Buckley Wealth Management Las Vegas, Nevada $392M AUM 28.21% 1-Year Est. Return
IPW
Inlet Private Wealth Jupiter, Florida $392M AUM 25.74% 1-Year Est. Return
TCM
Turas Capital Management Boston, Massachusetts $392M AUM
MA
Mezzasalma Advisors Tinton Falls, New Jersey $391M AUM 40.85% 1-Year Est. Return

Euclidean Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Euclidean Capital held 13 positions worth $889M, up 94% from $458M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Euclidean Capital deployed $359M of net new capital in Q4 2023, adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 7.7% of assets, down from 14% a quarter earlier.

On the sell side, the largest reduction was Surrozen, an estimated $14 trimmed.

  • Euclidean Capital added most to State Street SPDR S&P 500 ETF Trust in Q4 2023, an estimated $299M increase.
  • Euclidean Capital's biggest Q4 2023 reduction was Surrozen, cutting an estimated $14.
  • Euclidean Capital's ten largest holdings make up 100% of its $889M portfolio in Q4 2023.
  • Euclidean Capital opened 0 new positions and closed 0 in Q4 2023.
  • Euclidean Capital's portfolio value rose 94% quarter-over-quarter to $889M.

Based on Euclidean Capital's 13F filing for Q4 2023, filed 14 Feb 2024.